Enhancing the Yield of 10-HydroxycamptothecinGlucuronide Prodrug.

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 2017 第十一屆嘉南藥理大學藥理學院師生研究成果發表會 > Item 310902800/33574

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/33574

標題:	Enhancing the Yield of 10-HydroxycamptothecinGlucuronide Prodrug.
作者:	陳國輝邱沛芳
貢獻者:	藥學系
日期:	2017
上傳時間:	2022-01-25 14:45:14 (UTC+8)
摘要:	For chemotherapy, many chemotherapy target rapidly proliferating cells, these therapies might act at cell cycle. So the drug has not tumor specificity, it will cause severe side effects. In order to increase the tumor targeting, we accord to the strategy of prodrug. We design and synthesize glucuronide prodrug of 10-hydroxycamptothecin. Make the anti-tumor drug, 10-hydroxycamptothecin, conjugate with β-D-glucuronic acid to improve drug’s tumor specific and water solubility. Then, 10-hydroxycamptothecin connect conjugate with β-D-glucuronic acid via a self-immolative 3-methylpiperazine benzyl ether linker. The linker improve the prodrug affinity for β-glucuronidase. However, the benzyl ether linkage is nonpolar groups, which reduce water solubility, then will increase cytotoxity to normal cell. In order to improve solubility of prodrug. We created the 3-methylpiperazine group on benzyl ether, it is tertiary amine which will improve water solubility and reduce the prodrug impermeability to normal cell. When the spacer including the 3-methylpiperazine group on benzyl ether, it is more bulk group than benzyl ether, this benzyl group conduction with the 10-hydorxycamptothecin have poor yield. For solving this problem, the spacer conjugate the 2-amino-5-hydroxybenzaldehyde first, then conduction with tricyclic ketone to form 10-hydorxycamptothecin.
關聯:	2017 第十一屆嘉南藥理大學藥理學院師生研究成果發表會，起迄日：2017/05/02-2017/05/04
顯示於類別:	[藥理學院] 2017 第十一屆嘉南藥理大學藥理學院師生研究成果發表會 [藥學系(所)] 會議論文

文件中的檔案:

檔案	大小	格式	瀏覽次數
A04.pdf	785Kb	Adobe PDF	144	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....